Lilly drops push for Ebglyss PBS listing

Reimbursement terms make PBS listing “unviable” for eczema treatment, manufacturer claims  Eli Lilly will not proceed with plans to have its targeted IL-13 inhibitor, Ebglyss (lebrikizumab), listed on the Pharmaceutical Benefits Scheme (PBS), due to the reimbursement terms offered by the federal government.  The decision comes after the Pharmaceutical Benefits Advisory Committee (PBAC) recommended the